Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)

• Published in: BMC neurology Vol. 19; no. 1; pp. 191 - 8
• Main Authors: Loo, Li Shen, Plato, Brian M., Turner, Ira M., Case, Michael G., Raskin, Joel, Dowsett, Sherie A., Krege, John H.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.08.2019; BioMed Central; BMC
• Subjects: Adult; Analgesia; Analysis; Benzamides - administration & dosage; Benzamides - adverse effects; Care and treatment; Clinical trials; Double-Blind Method; Female; Headache; Humans; Lasmiditan; Male; Medical research; Middle Aged; Migraine; Migraine Disorders - drug therapy; Pain; Pain management; Phase 3; Piperidines - administration & dosage; Piperidines - adverse effects; Pyridines - administration & dosage; Pyridines - adverse effects; Recurrence; Recurrence (Disease); Rescue; Second dose; Serotonin Receptor Agonists - administration & dosage; Serotonin Receptor Agonists - adverse effects; Recurrence; Rescue; Phase 3; Lasmiditan; Second dose
• ISSN: 1471-2377; 1471-2377
• DOI: 10.1186/s12883-019-1420-5

We studied the efficacy and safety of a second dose of lasmiditan for acute treatment of migraine. SAMURAI and SPARTAN were double-blind, placebo-controlled Phase 3 studies in which individuals with migraine were randomized to oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo. Study drug was to be taken within 4 h (h) of onset of a migraine attack (moderate or severe pain). A second dose of study drug was provided for rescue (patient not pain-free at 2 h and took a second dose 2-24 h post-first dose) or recurrence (patient pain-free at 2 h, but experienced recurrence of mild, moderate, or severe migraine pain and took a second dose 2-24 h after first dose). Randomization to second dose occurred at baseline; patients originally assigned lasmiditan were randomized to the same lasmiditan dose or placebo (2:1 ratio), and those originally assigned placebo received placebo. Data from SAMURAI and SPARTAN were pooled for efficacy and safety assessment of a second dose of lasmiditan. The proportion of patients taking a second dose was lower with lasmiditan versus placebo, and decreased with increasing lasmiditan dose; the majority who took a second dose did so for rescue. In patients taking lasmiditan as first dose, outcomes (pain free, most bothersome symptom [MBS] free) at 2 h after a second dose for rescue were similar whether the second dose was lasmiditan or placebo (p > 0.05 in all cases). In patients taking lasmiditan for first dose, outcomes at 2 h after a second dose for recurrence were as follows: lasmiditan pooled versus placebo - pain free, 50% vs 32% (p > 0.05); MBS free, 71% vs 41% (p = 0.02); pain relief, 77% vs 52% (p = 0.03). In patients whose first dose was lasmiditan, the incidence of treatment emergent adverse events (TEAEs) reported after the second dose was similar whether second dose was lasmiditan or placebo. A second dose of lasmiditan showed some evidence of efficacy when taken for headache recurrence. There was no clear benefit of a second dose of lasmiditan for rescue treatment. The incidences of TEAEs were similar whether the second dose was lasmiditan or placebo. SAMURAI ( NCT02439320 ) [April 2015]. SPARTAN ( NCT02605174 ) [May 2016].